Tuesday

16th Jan 2018

Opinion

Why are our medicines so expensive?

  • 'Austerity politics mean people in Europe are also facing a growing treatment access gap' (Photo: isobrown)

In the lead-up to an inter ministerial meeting between EU and India next week, European trade negotiators continue to pressure India and other developing countries to accept so-called “free trade” agreements that favour patent monopolies, high medicines prices, and the interests of the pharmaceutical industry.

Instead, the EU should be promoting open innovation and should work to bring down the prices of essential medicines, both abroad and within its borders.

Thank you for reading EUobserver!

Subscribe now for a 30 day free trial.

  1. €150 per year
  2. or €15 per month
  3. Cancel anytime

EUobserver is an independent, not-for-profit news organization that publishes daily news reports, analysis, and investigations from Brussels and the EU member states. We are an indispensable news source for anyone who wants to know what is going on in the EU.

We are mainly funded by advertising and subscription revenues. As advertising revenues are falling fast, we depend on subscription revenues to support our journalism.

For group, corporate or student subscriptions, please contact us. See also our full Terms of Use.

If you already have an account click here to login.

For Europeans who have never had to worry about access to health care or medicines, it comes as a shock that the downward spiral of financial crisis and ensuing austerity politics have put at risk our once sacrosanct right to access affordable, quality health care.

Reading the agonizing stories of cancer patients in Greece who can no longer afford the medicines that keep them alive, or immigrants in Spain who no longer get costly AIDS cocktails because their health care is being revoked, it is clear we have our priorities wrong.

But why are our medicines so expensive?

For decades, Western countries have relied on an innovation model that provides generous incentives to pharmaceutical companies to develop and test medicines. Public funds support much of the early research for new medicines, and companies that bring new drugs to market receive tax credits and patents that let them charge monopoly prices and make high profits.

For a long time, wealthy countries with comprehensive health insurance coverage considered expensive medicines an acceptable price to pay for medical innovation and a booming pharmaceutical sector, since no one had to pay the full cost of medicines out-of-pocket.

Now that austerity measures are shifting these high cost to patients, however, we must ask - what is the point of having medical innovation if we cannot afford the therapies it delivers?

This, of course, is the situation that people living in low and middle income countries have confronted all along. For example, the price of life-saving hepatitis C medicines, sold under monopoly pricing by Merck and Roche can easily cost €15,000 per treatment.

Similarly, Novartis has maintained a global price of around €2,000 per month for its breakthrough cancer drug Glivec.

Treatment access gap

It is no surprise that virtually no one outside of rich countries can access these medicines. Now, austerity politics in the EU mean that poor, unemployed, and otherwise disadvantaged groups in Europe are also facing a growing treatment access gap.

We know from other countries that most medicines can be produced at a fraction of the price they cost in Europe. For instance, a generic version of Glivec is available in India at around €120 per month, much to the discontent of Novartis, who challenged India’s patent law in court to maintain its grip on profits.

Last week, after a seven year legal battle, patients won a landmark victory when India’s Supreme Court upheld the legality of the generic, thus safeguarding India’s role as a global hub for generic medicines.

Yet instead of finding ways to reduce the price of medicines, the European Commission’ is pursuing deals that would further restrict countries’ abilities to speed up generic availability and effective price competition. Following what Commissioner Karel De Gucht calls an “ambitious European free trade agenda”, they seek to promote the exportation of Europe's pharmaceutical products at high prices, favouring pharma companies over the health of the people.

EU India trade talks

In protracted closed door negotiations for an EU-India Free Trade Agreement, the Directorate General for Trade and corporate advisors continue to pressure India to accept provisions that undermine public health safeguards and favour corporate interests.

These include enhanced protection of patents and clinical data, which are known to delay entry of generic medicines into the market. Patients and health activists in countries such as Jordan and Guatemala have learnt the hard way that access to medicines is among the first issues to be compromised in such trade negotiations, seeing medicines prices soar once the agreements were signed.

In effect, the EU is pressuring India to make concessions that will undermine the health of millions of people worldwide, for whom India is their affordable pharmacy.

Rather than exporting its unsustainable model of patent-driven innovation and expensive medicines, Europe should stay focused on one of its greatest traditions - accessible health care for all.

While it could learn lessons from India about reducing medicine prices, Europe is ideally positioned to lead the way towards novel, open, and collaborative models of medical innovation that will ensure new medicines meet our health needs at prices people can afford.

We know this is possible. Even the head of GlaxoSmithKline Andrew Witty admits that the alleged $1 billion price tag for drug development - the chief excuse for high medicines prices - is “one of the great myths of the industry.”

In this age of financial difficulties, expensive medicines need not be.

The writer is the director of the Open Society Public Health Programme’s Access to Essential Medicines Initiative.

Focus

EU alternative-medicine safety rules will slim down access

Measures forcing the purveyors of alternative medicines to prove they are safe and that they have a long track-record of people believing they work will cut the number of herbal remedies and traditional Chinese medical products on the European market from 1 May.

Thousands march in India against EU trade deal

Thousands of HIV-positive protesters took to the streets in downtown New Delhi on Wednesday, concerned that an imminent EU-India free trade agreement will end the production of affordable life-prolonging drugs.

News in Brief

  1. Spanish anti-mafia prosecutor targets Russian officials
  2. Madrid to continue direct rule if Puigdemont re-elected
  3. Major variations in online banking take-up across EU
  4. No second EU referendum, says Corbyn
  5. German ministry warns against EU parliament's Dublin reform
  6. Vienna marches against far-right FPO party
  7. UK should pay more for Calais migrants, says French minister
  8. Portugal opposition elects new leader

Stakeholders' Highlights

  1. ILGA EuropeFreedom of Movement and Same-Sex Couples in Romania – Case Update!
  2. EU2017EEEstonia Completes First EU Presidency, Introduced New Topics to the Agenda
  3. Bio-Based IndustriesLeading the Transition Towards a Post-Petroleum Society
  4. ACCAWelcomes the Start of the New Bulgarian Presidency
  5. Mission of China to the EUPremier Li and President Tusk Stress Importance of Ties at ASEM Summit
  6. EU2017EEVAT on Electronic Commerce: New Rules Adopted
  7. European Jewish CongressChair of EU Parliament Working Group on Antisemitism Condemns Wave of Attacks
  8. Counter BalanceA New Study Challenges the Infrastructure Mega Corridors Agenda
  9. Dialogue PlatformThe Gülen Community: Who to Believe - Politicians or Actions?" by Thomas Michel
  10. Plastics Recyclers Europe65% Plastics Recycling Rate Attainable by 2025 New Study Shows
  11. European Heart NetworkCommissioner Andriukaitis' Address to EHN on the Occasion of Its 25th Anniversary
  12. ACCACFOs Risk Losing Relevance If They Do Not Embrace Technology

Latest News

  1. Macron's Chinese 'game of influence'
  2. EU's 'old men' must pressure on Poland on abortion rights
  3. Commission to float anti-'fake news' proposals in spring
  4. Sweden raises alarm on election meddling
  5. Bulgaria's corruption problem mars EU presidency start
  6. No new dawn for Europe under German coalition
  7. Bulgaria takes over, Germany's SPD votes This WEEK
  8. German coalition deal aims for 'Macron-lite' EU renewal

Stakeholders' Highlights

  1. UNICEFMake the Digital World Safer for Children & Increase Access for the Most Disadvantaged
  2. European Jewish CongressWelcomes Recognition of Jerusalem as the Capital of Israel and Calls on EU States to Follow Suit
  3. Mission of China to the EUChina and EU Boost Innovation Cooperation Under Horizon 2020
  4. European Gaming & Betting AssociationJuncker’s "Political" Commission Leaves Gambling Reforms to the Court
  5. AJC Transatlantic InstituteAJC Applauds U.S. Recognition of Jerusalem as Israel’s Capital City
  6. EU2017EEEU Telecom Ministers Reached an Agreement on the 5G Roadmap
  7. European Friends of ArmeniaEU-Armenia Relations in the CEPA Era: What's Next?
  8. Mission of China to the EU16+1 Cooperation Injects New Vigour Into China-EU Ties
  9. EPSUEU Blacklist of Tax Havens Is a Sham
  10. EU2017EERole of Culture in Building Cohesive Societies in Europe
  11. ILGA EuropeCongratulations to Austria - Court Overturns Barriers to Equal Marriage
  12. Centre Maurits CoppietersCelebrating Diversity, Citizenship and the European Project With Fundació Josep Irla